Vimarsana
Biggest News Aggregation in the World

Alisonk Wright News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alisonk Wright. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alisonk Wright Today - Breaking & Trending Today

Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes - Vimarsana News

Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes

Combined use of an SGLT2 inhibitor and GLP-1 receptor agonist is associated with reduced odds for major adverse cardiac and cerebrovascular events and heart failure in adults with type 2 diabetes, according to study findings. In an analysis of data from more than 300,000 adults with type 2 diabetes registered in three medical databases in England and Wales, the use of an SGLT2 inhibitor alone or

Source: healio.com
SGLT2is, SGLT2i/GLP-1RA May Prevent CV Events in T2DM - Vimarsana News

SGLT2is, SGLT2i/GLP-1RA May Prevent CV Events in T2DM

Current use of SGLT2is, GLP-1RAs, and their combination associated with significantly reduced risk of heart failure events.

Source: empr.com
SGLT2is, SGLT2i/GLP-1RA May Prevent CV Events in T2DM - Vimarsana News

SGLT2is, SGLT2i/GLP-1RA May Prevent CV Events in T2DM

THURSDAY, Feb. 17, 2022 (HealthDay News) -- For patients with type 2 diabetes, current use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and SGLT2is...